BioNexus Gene Lab Corp. — Operating Income by Fiscal Year
8 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/214d7a32-3a40-48b2-8ab2-463a28c0be74/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-3.0M | 2025-01-01 – 2025-12-31 | evidence 0001477932-26-002218 |
| FY 2024 | $-1.6M | 2024-01-01 – 2024-12-31 | evidence 0001477932-25-002725 |
| FY 2023 | $-2.6M | 2023-01-01 – 2023-12-31 | evidence 0001477932-24-002151 |
| FY 2022 | $-291.2k | 2022-01-01 – 2022-12-31 | evidence 0001477932-23-002002 |
| FY 2021 | $1.1M | 2021-01-01 – 2021-12-31 | evidence 0001477932-22-002089 |
| FY 2020 | $1.3M | 2020-01-01 – 2020-12-31 | evidence 0001477932-21-001795 |
| FY 2019 | $-275.7k | 2019-01-01 – 2019-12-31 | evidence 0001477932-20-001729 |
| FY 2018 | $59.9k | 2018-01-01 – 2018-12-31 | evidence 0001477932-20-001729 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).